Ashish Kacholia has invested INR 16 Cr (about $1.8 million) in a pre-series A fundraising round for healthtech startup ErlySign to advance its cancer diagnosis products.

According to the startup’s announcement, the new funds will be used for clinical trials, obtaining clearances from the Central Drugs Standard Control Organization (CDSCO), and launching ErlySign’s oral cancer detection kit.

Also read – Zypp Electric Raises ₹55.4 Crore in Ongoing Series C Funding Round

The business also says it has the first salivary biomarker-based test in India that can detect precancerous diseases long before symptoms show up. With a saliva sample, the biomarker-based test kit can identify oral precancerous diseases in 15 minutes, allowing for prompt action.

Also read – Climate Tech Startup Ecozen Secures $23 Mn Debt Funding

About ErlySign

Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign (also known as CURO Biosciences) is dedicated to developing innovative solutions for the early detection of oral cancer. The company is focused on advancing medical technology to enable more effective, timely diagnoses, helping to save lives through early intervention.

Also read – Skincare Startup Foxtale Secures $30 Mn Led by Kose Corporation